The Role of Melatonin and Leptin with gene expiration of ADCY3 in Obese people
DOI:
https://doi.org/10.52783/jns.v14.4185Keywords:
Obesity, Melatonin, Leptin, ADCY3Abstract
Background: obesity is linked to early death and poses a severe danger to public health. Non-communicable diseases, including type 2 diabetes, cardiovascular conditions, high blood pressure, and various cancers, significantly contribute to the global health burden. Studying the genes, hormones, and proteins that has correlation with obesity will help explain why some people, even in identical situations, are more likely to become obese than others.
Aim: Identify relationships between Melatonin and Leptin with gene expiration of ADCY3 gene and differences between obese and healthy individuals in obesity people.
Method: This study was carried out in laboratories of College of Science, Wasit University in Iraq form November 2023 to July 2024.This study were include 80 peoples the ages (18-50) they were measuring the BMI of them . Fifty obese people (25 male and 25 female) they are diagnosed clinically. The control group consists of 30 apparently healthy individuals (15 male and 15 female). The current study was in agreement with hospital ethics and approvals from all participants. Measuring melatonin, leptin and Gene (ADCY3) expiration in obese and control groups by EIESA assay.
Results: The Results was evaluated at (P ≤ 0.05) value, significantly higher (P= 0.034) mean levels of melatonin hormone in obese person (167.12±12.11) but in healthy control group (124.76±5.84).also, Significantly higher (P= 0.002) mean levels of leptin hormone in obese person (1.47± 0.061) but in healthy control group (2.35 ± 0.411).Mean level of ADCY3 were (1.29 ± 0.19) in obesity people and (2.01 ± 0.29) in healthy control group, data showed highly significantly (P= 0.001) decreasing of mean level of ADCY3 in obesity people when compared with healthy control group. Moreover results showed highly significant(r=0.360, p= 0.025) Positive correlation Leptin and Melatonin .Furthermore, highly negative correlation between ADCY3 and Melatonin (r=-0.503, p= 0.001), and ADCY3 and Leptin (r=-0.391, p= 0.004).
Conclusions: It is concluded from the present study that the gene expression of ADCY3 and Leptin hormone, Melatonin hormone important roles in the development and severity of obesity.
Downloads
Metrics
References
Carbone, S. (2013). Obesity and Diastolic Heart Failure: Is Inflammation the Link? Translational Medicine, 03(03). https://doi.org/10.4172/2161-1025.1000e124
Vick, L. V., Canter, R. J., Monjazeb, A. M., & Murphy, W. J. (2023). Multifaceted effects of obesity on cancer immunotherapies: Bridging preclinical models and clinical data. Seminars in Cancer Biology, 95, 88–102. https://doi.org/10.1016/j.semcancer.2023.07.004
Ribiere, C., & Plut, C. (2005). Nutritional regulation of leptin signaling. Current Hypertension Reports, 7(1), 11–16. https://doi.org/10.1007/s11906-005-0049-5
Çakır, I., Bagchi, R. A., White, A., Lin, J. D., Cone, R. D., Wang, Q., Mckinsey, T. A., Hagen, S., Ghamari-Langroudi, M., Porter, D. T., Lee, P., Jana, S., Hadley, C. K., Pan, P. L., & Litt, M. J. (2022). Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity. Nature Metabolism, 4(1), 44–59. https://doi.org/10.1038/s42255-021-00515-3
Szewczyk‐Golec, K., Woźniak, A., & Reiter, R. J. (2015). Inter-relationships of the chronobiotic, melatonin, with leptin and adiponectin: implications for obesity. Journal of Pineal Research, 59(3), 277–291. https://doi.org/10.1111/jpi.12257
Guan, Q., Wang, Z., Dong, Y., Cao, J., & Chen, Y. (2021). Mechanisms of Melatonin in Obesity: A Review. International Journal of Molecular Sciences, 23(1), 218. https://doi.org/10.3390/ijms23010218
Mahmoud, R., Kimonis, V., & Butler, M. G. (2022). Genetics of obesity in humans: Aclinical review. International Journal of Molecular Sciences, 23(19), 11005.https://doi.org/10.3390/ijms231911005
Wu, L., Shen, C., Seed Ahmed, M., Gu, H. F., & Östenson, C. ‐G. (2016). Adenylate cyclase 3: a new target for anti-obesity drug development. Obesity Reviews, 17(9), 907–914. https://doi.org/10.1111/obr.12430
Daniel W.W., (2018). Biostatistics: A Foundation for Analysis in the Health Sciences, John Wiley & Sons New York.
Delpino, F. M., & Figueiredo, L. M. (2021). Melatonin supplementation and anthropometric indicators of obesity: A systematic review and meta-analysis. Nutrition, 91–92.
Bence, K. K., Hotamisligil, G. S., Xue, B., Delibegovic, M., Neel, B. G., Kahn, B. B., & Gorgun, C. Z. (2006). Neuronal PTP1B regulates body weight, adiposity and leptin action. Nature Medicine, 12(8), 917–924. https://doi.org/10.1038/nm1435
Münzberg, H., Bates, S. H., Björnholm, M., & Myers, M. G. (2005). Leptin receptor action and mechanisms of leptin resistance. Cellular and Molecular Life Sciences, 62(6). https://doi.org/10.1007/s00018-004-4432-1
Myers, M. G., Cowley, M. A., & Münzberg, H. (2008). Mechanisms of Leptin Action and Leptin Resistance. Annual Review of Physiology, 70(1), 537–556. https://doi.org/10.1146/annurev.physiol.70.113006.100707
Wu, L., Shen, C., Seed Ahmed, M., Gu, H. F., & Östenson, C. ‐G. (2016). Adenylate cyclase 3: a new target for anti-obesity drug development. Obesity Reviews, 17(9), 907–914. https://doi.org/10.1111/obr.12430
Fitzpatrick, M., & Solberg Woods, L. C. (2023). Adenylate cyclase 3: a potential genetic link between obesity and major depressive disorder. Physiological Genomics, 56(1), 1–8. https://doi.org/10.1152/physiolgenomics.00056.2023
Alonso-Vale, M. I. C., Neto, J. C., Lima, F. B., Peres, S. B., Andreotti, S., Anhê, G. F., & Das Neves Borges-Silva, C. (2004). Melatonin enhances leptin expression by rat adipocytes in the presence of insulin. American Journal of Physiology-Endocrinology and Metabolism, 288(4), E805–E812. https://doi.org/10.1152/ajpendo.00478.2004
Wang, P.-H., Ji, L.-D., & Xu, J. (2023). Molecular mechanisms of the melatonin receptor pathway linking circadian rhythm to type 2 diabetes mellitus. Nutrients, 15(6). https://doi.org/10.3390/nu15061406
Saeed, S., Bonnefond, A., Tamanini, F., Mirza, M. U., Manzoor, J., Janjua, Q. M., Din, S. M., Gaitan, J., Milochau, A., Durand, E., Vaillant, E., Haseeb, A., De Graeve, F., Rabearivelo, I., Sand, O., Queniat, G., Boutry, R., Schott, D. A., Ayesha, H., Ali, M., Khan, W. I., Butt, T. A., Rinne, T., Stumpel, C., Abderrahmani, A., Lang, J., Arslan, M., & Froguel, P. (2018). Loss-of-function mutations in ADCY3 cause monogenic severe obesity. Nature Genetics, 50(2), 175–179. https://doi.org/10.1038/s41588-017-0023-6
Goni, L., Riezu-Boj, J. I., Milagro, F. I., Corrales, F. J., Ortiz, L., Cuervo, M., & Martínez, J. A. (2018). Interaction between an ADCY3 genetic variant and two weight-lowering diets affecting body fatness and body composition outcomes depending on macronutrient distribution: A randomized trial. Nutrients, 10(6), 789. https://doi.org/10.3390/nu10060789
Toumba, M., Fanis, P., Vlachakis, D., Neocleous, V., Phylactou, L. A., Skordis, N., Mantzoros, C. S., & Pantelidou, M. (2021). Molecular modelling of a novel ADCY3 variant predicts a molecular target for tackling obesity. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2021.5065
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
